Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration

American Journal of Health-System Pharmacy

Volumn 64, Issue 11, 2007, Pages 1209-1213

  Trissel, Lawrence A ^a   Trusley, Craig ^b   Ben, Michel ^b   Kupiec, Thomas C ^b  

^a TriPharma Research   (United States)

^b Analytical Research Laboratories   (United States)

Author keywords

Antiemetics; Closures; Color; Concentration; Containers; Contamination; Fentanyl citrate; Glass; Hydromorphone hydrochloride; Incompatibilities; Injections; Meperidine hydrochloride; Morphine sulfate; Opiate agonists; Palonosetron hydrochloride; Particle size

Indexed keywords

OPIATE AGONIST; PALONOSETRON;

ARTICLE; COLOR; DRUG INCOMPATIBILITY; DRUG MIXTURE; DRUG STABILITY; DRUG STORAGE; PARTICLE SIZE; PARTICULATE MATTER; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; TURBIDITY;

EID: 34249824909     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060355     Document Type: Article

References (21)

1. Aloxi (palonosetron hydrochloride) package insert. Bloomington, MN: MGI Pharma, Inc.; 2006 Jan.
2. Siddiqui MA, Scott LJ. Palonosetron. Drugs. 2004; 64:1125-32.
3. Rubinstein EB. Palonosetron: a unique 5-HT(3) receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2004; 2:284-8.
4. Eglen RM, Lee CH, Smith WL et al. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol. 1995; 114:860-6.
5. Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solutions. Ann Pharmacother. 2004; 38:1608-11.
6. Trissel LA, Zhang YP. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration. J. Oncol Pharm Pract. 2004; 10:191-5.
7. Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacother. 2005; 39:280-3.
8. Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl with topotecan HCl and irinotecan HCl during simulated Y-site administration. Int J Pharm Compound. 2005; 9:238-41.
9. Trissel LA, Xu QA. Physical and chemical compatibility of palonosetron HCl with lorazepam and midazolam HCl during simulated Y-site administration. Int J Pharm Compound. 2005; 9:235-7.
10. Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound. 2005; 9:320-2.
11. Xu QA, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with cyclophosphamide and ifosfamide during simulated Y-site administration. Am J Health-Syst Pharm. 2005; 62:1998-2000.
12. Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron HCl with dacarbazine and methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound. 2006; 10:234-6.
13. Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health-Syst Pharm. 2004; 61:1596-8.
14. Allen LV Jr, Levinson RS, Phisutsinthrop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm. 1977; 34:939-43.
15. Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm. 1992; 49:1716-9.
16. Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm. 1993; 50:300-4.
17. Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm. 1993; 50:2359-63.
18. Palonosetron hydrochloride i.v. injection 0.05 mg/mL and 0.15 mg/mL end-product test procedure. Minneapolis: MGI Pharma, Inc., undated.
19. Christen C, Johnson CE, Walters JR. Stability of bupivacaine hydrochloride and hydromorphone hydrochloride during simulated epidural co-administration. Am J Health-Syst Pharm. 1996; 53:170-3.
20. Stiles ML, Tu YH, Allen LV Jr. Stability of morphine sulfate in portable pump reservoirs during storage and simulated administration. Am J Hosp Pharm. 1989; 46:1404-7.
21. Roos PJ, Glerum JH, Meilink JW. Stability of sufentanil citrate in a portable pump reservoir, a glass container and a polyethylene container. Pharm Weekbl Sci. 1992; 14:196-200.